-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Revolution Medicines, Raises Price Target to $215

Benzinga·07/06/2026 12:33:41
Listen to the news
Mizuho analyst Joseph Catanzaro maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $185 to $215.